EOSE day trade study

EOSE  sold on 09/30/2024 gained 101.03 

buy back 2.68 20 share on 10/01/2024 gained= 5 $ 

 

UAVS net loss 262.31

 

GEVO fill the short 9/30/2024

 

GEVO	$1.57	$1.6096  Price as of 9/30/2024	N/A--	-0.45%  -$0.08	-$0.1004	$17.70	+2.61%  +$0.45	11	$1.57/share	Dividend Reinvestment?	6,741,405	1.58%	08/08/2024	N/A	--	N/A	N/A	-5.35	$0.48	$1.84	--	--

HUSA fill the short on 9/30/2024

 

HUSA	$1.25	$1.105  Price as of 9/30/2024	N/A--	+0.66%  +$0.08	+$0.015	$12.21	-11.33%  -$1.56	11	$1.25/share	Dividend Reinvestment?	194,901	1.08%	08/14/2024	N/A	--	N/A	N/A	-3.80	$0.96	$2.81	--	--

RKLB progressive

 

09 26 2024 daily net loss 16 -120 stock to fix

 

daily 9 26 2024 2 to 4

 

Daily 9 26 2024

 

SESAI

 The drop in SES AI's stock price today appears to be influenced by a significant sell-off by Temasek Holdings, a major shareholder. Over the past few days, Temasek unloaded a substantial portion of its shares, totaling over $630,000 in value between September 19 and 20, 2024. These sales were part of a broader pattern, with Temasek reducing its stake across multiple transactions, likely leading to downward pressure on the stock [oai_citation:3,Temasek Holdings Reduces Stake in SES AI Corp](https://au.finance.yahoo.com/news/temasek-holdings-reduces-stake-ses-061651840.html) [oai_citation:2,Holdings (Private) Ltd Temasek Sells 253,119 Shares of SES AI Co. (NYSE:SES) Stock](https://www.marketbeat.com/instant-alerts/nyse-ses-insider-buying-and-selling-2024-09-23/). 

Investors often react negatively when a major stakeholder reduces its position, as it may signal a lack of confidence in the short-term performance of the company. Additionally, SES AI has been facing challenges, such as missing earnings expectations and navigating uncertainties in the market [oai_citation:1,Holdings (Private) Ltd Temasek Sells 253,119 Shares of SES AI Co. (NYSE:SES) Stock](https://www.marketbeat.com/instant-alerts/nyse-ses-insider-buying-and-selling-2024-09-23/).

SNGX

 The future outlook for Soligenix (SNGX) stock is mixed with both potential upside and high risks. Here's an overview of what analysts are predicting:

1. Short-Term Expectations:

   • In the near term, SNGX is facing several negative technical indicators. The stock has been experiencing sell signals from its moving averages, and its trend is currently downward, suggesting potential weakness in the coming days or weeks. Analysts have a cautious view, classifying it as a "strong sell" due to ongoing downward momentum and lack of positive signals​(
     Stock Screener, Chart, and Price
     )​(
     StockInvest
     ).

2. Long-Term Potential:

   • Despite the short-term negativity, the stock has a wide range of price forecasts for the next few years. Some predictions for 2024 suggest a potential recovery with a target price as high as $10.86 by the end of the year​(
     Stock Screener, Chart, and Price
     ). By 2025, the stock could experience significant growth, with estimates as high as $44.23, largely dependent on the company's progress in its late-stage biopharmaceutical developments​(
     Stock Screener, Chart, and Price
     )​(
     StockInvest
     ).

3. Risks:

   • SNGX is highly volatile, with sharp fluctuations in its stock price, making it a high-risk investment. Liquidity issues and lower trading volumes increase the uncertainty, which could lead to significant price swings​(
     StockInvest
     ).

In summary, while there is potential for strong gains in the long term, particularly if the company's biopharmaceutical products succeed, the short-term outlook remains bearish. Investors should proceed with caution, considering the stock's volatility and technical challenges.

09/13/2024 gain

 

SMMT

 Summit Therapeutics (SMMT) stock has surged significantly today, continuing a trend from earlier this week due to the positive results from its Phase III trial of Ivonescimab, a promising lung cancer therapy. The trial showed that Ivonescimab reduced disease progression by 49% compared to Merck's Keytruda, which is a leading treatment in this space. This breakthrough suggests that Ivonescimab could potentially become a more effective treatment, leading to a lot of investor interest. Multiple analysts have raised their price targets, further fueling the stock's upward momentum​(

MarketBeat

)​(

Benzinga

)​(

MarketBeat

).

PDYN

Searched 4 sites

Palladyne AI Corp (PDYN) saw a significant stock price increase today, rising by over 27%. The surge is attributed to several factors, including technical momentum as the stock recently crossed its 20-day moving average with a rise of over 18%, indicating growing investor interest​(

MarketBeat

)​(

Seeking Alpha

). Additionally, the company's recent updates about its artificial intelligence and machine learning advancements, especially in robotics platforms, have likely contributed to the positive sentiment. The company's focus on enhancing the adaptability of robots in dynamic environments has positioned it well across industries like manufacturing, logistics, and defense, which are expected to see increased demand​ (

FINVIZ

).